74:). However, FDCs may also target multiple diseases/conditions. In cases of FDCs targeting multiple conditions, such conditions might often be related—in order to increase the number of prospective patients who might be likely to use a given FDC product. This is because each FDC product is mass-produced, and thus typically requires having a critical mass of potentially applicable patients in order to justify its manufacture, distribution, stocking, etc.
489:
46:. Terms like "combination drug" or "combination drug product" can be common shorthand for an FDC product (since most combination drug products are currently FDCs), although the latter is more precise if in fact referring to a mass-produced product having a predetermined combination of drugs and respective dosages (as opposed to
301:
occurs from using an FDC, it may be difficult to identify the active ingredient responsible for causing the reaction. This problem might be alleviated by starting the medications individually and monitoring for reactions, and then switching to an FDC when no problems have been observed (assuming of
285:
There may not be an FDC available with the appropriate drugs and/or in the most appropriate respective strength(s) for a given patient, which can lead to some patients getting too much of an ingredient and others getting too little, as the AAO notes that FDCs "limit clinicians' ability to customize
252:
that may be specific for the relative dosages in a given FDC product, providing a simpler overview compared to when looking at the profiles of each single drug individually. Such combined profiles can also include effects caused by interaction between the individual drugs that may be omitted in
58:
of medical products—such as device/drug combinations as opposed to drug/drug combinations. When a combination drug product (whether fixed-dose or not) is a "pill" (i.e., a tablet or capsule), then it may also be a kind of
521:
305:
Formulation scientists experience challenges in the development stages of multi-drug formulations such as compatibility issues among active ingredients and excipients affecting solubility and dissolution
241:
of patients. Pill burden is not only the number of pills needing to be taken, but also the associated burdens such as keeping track of several medications, understanding their various instructions, etc.
264:
with each other. However, FDCs may interact with other drugs that a patient is taking, so the usual medical and pharmaceutical precautions against drug-drug interactions or DDIs remain warranted.
275:, a company may obtain exclusive rights to sell a particular FDC or formulation thereof, even though the individual active ingredients and many therapeutic uses thereof may be off-patent.
286:
dosing regimens." In such cases an alternative possibility (instead of an FDC) is to use custom-compounded polypills prepared by a compounding pharmacist according to a prescription. (
514:
377:
54:). And it should also be distinguished from the term "combination product" in medical contexts, which without further specification can refer to products that combine different
507:
650:
164:
67:
93:
684:
213:
572:
375:
625:
127:
405:
257:
209:
174:
493:
16:
This article is about fixed drug combinations as treatments. For two synergistic drugs chemically linked together, see
205:
271:
as a way to in effect extend proprietary rights and marketability of a drug product. Since FDCs may be protected by
711:
557:
287:
589:
645:
599:
268:
201:
706:
630:
298:
234:
66:
Initially, fixed-dose combination drug products were developed to target a single disease (such as with
290:
is the practice of preparing individualized drug products for individual patients, which can aid with
110:
226:
187:
260:
in the United States), the active ingredients used in the FDCs are unlikely to exhibit adverse
567:
542:
457:
439:
420:"Challenges and Opportunities in Achieving Bioequivalence for Fixed-Dose Combination Products"
357:
156:
145:
39:
562:
447:
431:
347:
339:
261:
245:
178:
99:
680:
499:
381:
118:
114:
667:
635:
452:
419:
352:
327:
249:
163:
sulfate/dextroamphetamine saccharate/amphetamine aspartate monohydrate) — treatment of
106:
700:
675:
609:
579:
291:
238:
160:
51:
43:
617:
435:
225:
In addition to simply being a means of facilitating the general advantages of
168:
131:
443:
308:
If one drug is contraindicated for a patient, whole FDC cannot be prescribed.
229:, specific advantages of fixed-dose combination (FDC) drug products include:
461:
393:
384:, BAYVIEW PHARMACY'S PRESCRIPTION COMPOUNDING BLOG,Apr 01, 2009 @ 08:09 AM.
361:
488:
343:
657:
584:
195:
191:
182:
152:
139:
60:
594:
87:
547:
272:
135:
122:
83:
17:
71:
23:
Drug that contains two or more active pharmaceutical ingredients
503:
302:
course that it's the active ingredient causing the problem).
256:
Since FDCs are reviewed by regulating agencies (such as the
394:
Combination
Products-U.S. Food and Drug Administration
374:"5-in-1 PolyPill Treatment May Prevent Heart Disease"
244:
Ability to compose combined profiles of for example
666:
608:
535:
406:Glaucoma Medical Therapy-Principles and Management
515:
418:Mitra, Amitava; Wu, Yunhui (September 2012).
8:
522:
508:
500:
38:) is a medicine that includes two or more
451:
351:
651:List of medicine contamination incidents
267:FDC drug products may be developed by a
165:attention deficit hyperactivity disorder
530:Combined substance use and adulteration
318:
92:For more common combination drugs, see
94:WHO Model List of Essential Medicines
7:
685:List of reagent testing color charts
332:Canadian Medical Association Journal
214:treatment and management of COVID-19
573:List of polysubstance combinations
14:
202:Nirmatrelvir/ritonavir (Paxlovid)
626:Counterfeit illegal drug selling
487:
128:Glucose/fructose/phosphoric acid
1:
177:— pain treatment, especially
328:"Reducing the "pill burden""
258:Food and Drug Administration
210:Food and Drug Administration
175:Aspirin/paracetamol/caffeine
84:Codrug § Common codrugs
206:emergency use authorization
88:Synergy § Drug synergy
730:
558:Combined drug intoxication
288:Pharmaceutical compounding
91:
81:
15:
436:10.1208/s12248-012-9378-x
253:individual drug profiles.
590:Polysubstance dependence
78:Common combination drugs
646:Counterfeit medications
326:Collier, Roger (2012).
536:Combined substance use
269:pharmaceutical company
32:fixed-dose combination
631:Clandestine chemistry
344:10.1503/cmaj.109-4076
299:adverse drug reaction
235:medication compliance
42:combined in a single
496:at Wikimedia Commons
474:Kennedy Seele, 2020
111:8-chlorotheophylline
227:combination therapy
188:Caffeine/ergotamine
68:antiretroviral FDCs
404:Peter A. Netland,"
380:2014-02-27 at the
146:Prescription drugs
117:) — used to treat
40:active ingredients
712:Combination drugs
694:
693:
568:Polysubstance use
543:Active metabolite
494:Combination drugs
492:Media related to
262:drug interactions
157:dextroamphetamine
134:taken to relieve
50:polypharmacy via
719:
563:Drug interaction
553:Combination drug
524:
517:
510:
501:
491:
475:
472:
466:
465:
455:
424:The AAPS Journal
415:
409:
402:
396:
391:
385:
372:
366:
365:
355:
338:(2): E117–E118.
323:
246:pharmacokinetics
237:by reducing the
208:(EUA) by the US
179:tension headache
100:Over-the-counter
63:" or combopill.
28:combination drug
729:
728:
722:
721:
720:
718:
717:
716:
697:
696:
695:
690:
681:Reagent testing
662:
604:
531:
528:
484:
479:
478:
473:
469:
417:
416:
412:
403:
399:
392:
388:
382:Wayback Machine
373:
369:
325:
324:
320:
315:
282:
250:adverse effects
223:
190:— treatment of
119:motion sickness
115:diphenhydramine
97:
90:
80:
24:
21:
12:
11:
5:
727:
726:
723:
715:
714:
709:
699:
698:
692:
691:
689:
688:
678:
672:
670:
668:Harm reduction
664:
663:
661:
660:
655:
654:
653:
648:
640:
639:
638:
633:
628:
622:Illegal drugs
620:
614:
612:
606:
605:
603:
602:
597:
592:
587:
582:
577:
576:
575:
565:
560:
555:
550:
545:
539:
537:
533:
532:
529:
527:
526:
519:
512:
504:
498:
497:
483:
482:External links
480:
477:
476:
467:
430:(3): 646–655.
410:
397:
386:
367:
317:
316:
314:
311:
310:
309:
306:
303:
295:
281:
278:
277:
276:
265:
254:
248:, effects and
242:
222:
219:
218:
217:
212:(FDA) for the
199:
185:
172:
143:
142:
125:
107:Dimenhydrinate
79:
76:
22:
13:
10:
9:
6:
4:
3:
2:
725:
724:
713:
710:
708:
705:
704:
702:
686:
682:
679:
677:
676:Drug checking
674:
673:
671:
669:
665:
659:
656:
652:
649:
647:
644:
643:
641:
637:
634:
632:
629:
627:
624:
623:
621:
619:
616:
615:
613:
611:
607:
601:
598:
596:
593:
591:
588:
586:
583:
581:
578:
574:
571:
570:
569:
566:
564:
561:
559:
556:
554:
551:
549:
546:
544:
541:
540:
538:
534:
525:
520:
518:
513:
511:
506:
505:
502:
495:
490:
486:
485:
481:
471:
468:
463:
459:
454:
449:
445:
441:
437:
433:
429:
425:
421:
414:
411:
407:
401:
398:
395:
390:
387:
383:
379:
376:
371:
368:
363:
359:
354:
349:
345:
341:
337:
333:
329:
322:
319:
312:
307:
304:
300:
296:
293:
289:
284:
283:
280:Disadvantages
279:
274:
270:
266:
263:
259:
255:
251:
247:
243:
240:
236:
232:
231:
230:
228:
220:
215:
211:
207:
203:
200:
197:
193:
189:
186:
184:
180:
176:
173:
170:
166:
162:
158:
154:
151:
150:
149:
147:
141:
137:
133:
129:
126:
124:
120:
116:
112:
108:
105:
104:
103:
101:
95:
89:
85:
77:
75:
73:
70:used against
69:
64:
62:
57:
53:
49:
45:
41:
37:
33:
29:
19:
707:Dosage forms
610:Adulteration
580:Polypharmacy
552:
470:
427:
423:
413:
400:
389:
370:
335:
331:
321:
292:polypharmacy
224:
144:
98:
65:
55:
47:
35:
31:
27:
25:
239:pill burden
167:(ADHD) and
161:amphetamine
102:medicines:
52:compounding
44:dosage form
701:Categories
642:Medicines
618:Drug fraud
313:References
221:Advantages
204:— granted
194:, such as
169:narcolepsy
132:antiemetic
82:See also:
48:customized
444:1550-7416
233:Improved
198:headache.
192:headaches
658:Impurity
585:Polypill
462:22684403
378:Archived
362:22231682
196:migraine
183:migraine
159:sulfate/
153:Adderall
140:vomiting
61:polypill
600:Synergy
595:Prodrug
453:3385830
353:3273525
273:patents
636:Lacing
548:Codrug
460:
450:
442:
360:
350:
297:If an
136:nausea
123:nausea
86:, and
18:codrug
56:types
30:or a
458:PMID
440:ISSN
358:PMID
181:and
138:and
121:and
72:AIDS
448:PMC
432:doi
348:PMC
340:doi
336:184
36:FDC
703::
456:.
446:.
438:.
428:14
426:.
422:.
356:.
346:.
334:.
330:.
294:.)
148::
130:—
26:A
687:)
683:(
523:e
516:t
509:v
464:.
434::
408:"
364:.
342::
216:.
171:.
155:(
113:/
109:(
96:.
59:"
34:(
20:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.